Nanologica AB (publ) (STO:NICA)
Sweden
· Delayed Price · Currency is SEK 0.384
-0.016 (-4.00%)
Mar 9, 2026, 5:23 PM CET
Nanologica AB Revenue
In the year 2025, Nanologica AB had annual revenue of 21.13M SEK with 45.32% growth. Nanologica AB had revenue of 5.21M in the quarter ending December 31, 2025, a decrease of -22.50%.
Revenue
21.13M
Revenue Growth
+45.32%
P/S Ratio
1.61
Revenue / Employee
1.11M
Employees
19
Market Cap
33.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.13M | 6.59M | 45.32% |
| Dec 31, 2024 | 14.54M | 9.87M | 211.17% |
| Dec 31, 2023 | 4.67M | -1.16M | -19.92% |
| Dec 31, 2022 | 5.83M | -8.91M | -60.43% |
| Dec 31, 2021 | 14.75M | -3.59M | -19.58% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 2cureX AB | 1.98M |
| AcouSort AB | 10.43M |
| Pila Pharma AB | 1.13M |
| ExpreS2ion Biotech Holding AB | 10.85M |
| Alzinova AB | 26.12M |
| Aptahem AB | 2.59M |
| Biovica International AB | 9.89M |
| Novakand Pharma AB | 14.00K |